Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciclesonide Nasal Spray in Children with SAR
NCT00305487Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2006
- Primary completion
- Oct 2006
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ciclesonide in seasonal allergic rhinitis (SAR) (3 arms), sponsored by AstraZeneca. Primary endpoint: Reflective Total Nasal Symptom Score at 2 weeks. Started Mar 2006; status: completed.
02
Drugs
ciclesonide
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT00305487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00305487.